Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.30)
# 378
Out of 4,876 analysts
231
Total ratings
41.98%
Success rate
20.92%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $4.72 | +238.98% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $7.10 | +40.85% | 4 | May 15, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $11.15 | +169.06% | 6 | May 14, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | $25 | $8.99 | +178.24% | 2 | May 14, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $113 → $112 | $49.84 | +124.72% | 19 | May 7, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $23 | $19.48 | +18.07% | 7 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $163 → $81 | $17.11 | +373.41% | 16 | May 7, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.38 | +194.12% | 16 | Apr 28, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $67 → $123 | $83.22 | +47.80% | 6 | Mar 27, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $90 | $1.83 | +4,818.03% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.66 | +163.16% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $54.50 | +142.20% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $18.16 | +37.67% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $36.52 | +223.11% | 18 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 | $31.16 | +15.53% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $20.28 | +230.37% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.93 | +254.13% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $9.86 | +194.12% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.25 | +423.08% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $0.99 | +705.15% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $13.86 | +318.47% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.39 | +360.25% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.75 | +213.04% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $4.11 | +240.63% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.12 | +513.21% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.42 | +1,378.87% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.94 | +541.57% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.60 | +1,150.00% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $2.96 | +678.05% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.02 | +88,135.29% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.63 | +6,447.43% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $3.42 | +11,595.91% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.76 | +11,158.28% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.42 | +2,325.88% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.17 | +3,746.15% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.98 | +1,017.77% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.47 | +3,981.63% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.30 | +6,823.08% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.81 | +139,126.52% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.44 | +36,263.64% | 1 | Jan 9, 2020 |
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $4.72
Upside: +238.98%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $7.10
Upside: +40.85%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $11.15
Upside: +169.06%
Zevra Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $25
Current: $8.99
Upside: +178.24%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $113 → $112
Current: $49.84
Upside: +124.72%
Rigel Pharmaceuticals
May 7, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $19.48
Upside: +18.07%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $17.11
Upside: +373.41%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.38
Upside: +194.12%
Soleno Therapeutics
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $83.22
Upside: +47.80%
X4 Pharmaceuticals
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $1.83
Upside: +4,818.03%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.66
Upside: +163.16%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $54.50
Upside: +142.20%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $18.16
Upside: +37.67%
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $36.52
Upside: +223.11%
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $31.16
Upside: +15.53%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $20.28
Upside: +230.37%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $5.93
Upside: +254.13%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $9.86
Upside: +194.12%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.25
Upside: +423.08%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $0.99
Upside: +705.15%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $13.86
Upside: +318.47%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.39
Upside: +360.25%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.75
Upside: +213.04%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $4.11
Upside: +240.63%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $2.12
Upside: +513.21%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.42
Upside: +1,378.87%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.94
Upside: +541.57%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.60
Upside: +1,150.00%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.96
Upside: +678.05%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.02
Upside: +88,135.29%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.63
Upside: +6,447.43%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $3.42
Upside: +11,595.91%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.76
Upside: +11,158.28%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $7.42
Upside: +2,325.88%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.17
Upside: +3,746.15%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.98
Upside: +1,017.77%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.47
Upside: +3,981.63%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.30
Upside: +6,823.08%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.81
Upside: +139,126.52%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.44
Upside: +36,263.64%